
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems Inc. has demonstrated a robust financial performance with gross margins expanding significantly from 48.8% in FY22 to an estimated 53.4% in 2025, reflecting efficient cost management and operational improvements. The company's revenue has increased by approximately 11%, with the Cardiovascular segment also registering an 11% growth, indicating strong demand for its medical device products amidst rising procedure volumes. Furthermore, an increase in physician reimbursement rates for key procedures is expected to enhance product adoption, which, combined with a positive growth outlook in the Endoscopy segment, supports a favorable long-term perspective on the company’s financial health.
Bears say
Merit Medical Systems has reported OEM revenue of $48.1 million, falling short of expectations of $58.3 million, indicating potential weaknesses in sales performance. The company's prospects are further undermined by risks such as poorer than anticipated margin performance, free cash flow issues, and slower growth in the critical Chinese market, which is under pressure from value-based procurement and macroeconomic challenges. Additionally, the bear case scenario suggests revenue growth may be limited to 5% or less, driven by difficulties related to recent acquisitions and new product launches, which could lead to further contraction in operating margins and below-consensus earnings.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares